Catheter Precision (NYSEAMERICAN:VTAK) Posts Earnings Results, Beats Estimates By $18.02 EPS

Catheter Precision (NYSEAMERICAN:VTAK) issued its quarterly earnings results on Tuesday. The company reported ($2.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($20.90) by $18.02, FiscalAI reports. Catheter Precision had a negative return on equity of 208.54% and a negative net margin of 2,333.29%.

Catheter Precision Price Performance

NYSEAMERICAN:VTAK traded down $0.04 during midday trading on Tuesday, reaching $1.01. The stock had a trading volume of 112,379 shares, compared to its average volume of 3,183,459. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.46 and a current ratio of 0.46. The firm has a fifty day simple moving average of $1.60 and a two-hundred day simple moving average of $2.04. Catheter Precision has a 12-month low of $1.01 and a 12-month high of $15.68.

Institutional Trading of Catheter Precision

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC purchased a new position in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned 2.08% of Catheter Precision as of its most recent SEC filing. Institutional investors own 20.34% of the company’s stock.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.